Oncolytics Biotech (TSE:ONC) Shares Pass Above 200-Day Moving Average – Time to Sell?

Oncolytics Biotech Inc. (TSE:ONC)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$1.40 and traded as high as C$1.40. Oncolytics Biotech shares last traded at C$1.40, with a volume of 181,909 shares changing hands.

Analysts Set New Price Targets

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Price Performance

The firm has a 50-day moving average of C$1.38 and a 200 day moving average of C$1.40. The company has a market capitalization of C$107.60 million, a PE ratio of -3.68 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.